| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nanexa AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.10 |
| 52 Week High | SEK 0.15 |
| 52 Week Low | SEK 0.028 |
| Beta | 1.77 |
| 11 Month Change | -17.48% |
| 3 Month Change | 57.12% |
| 1 Year Change | 129.64% |
| 33 Year Change | -71.65% |
| 5 Year Change | n/a |
| Change since IPO | -90.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 40M | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.5% | -3.6% | -2.2% |
| 1Y | 129.6% | -3.5% | 13.3% |
Return vs Industry: 40M exceeded the German Medical Equipment industry which returned -2.7% over the past year.
Return vs Market: 40M exceeded the German Market which returned 13.6% over the past year.
Price Volatility
| 40M volatility | |
|---|---|
| 40M Average Weekly Movement | 18.9% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 40M's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 40M's weekly volatility has decreased from 26% to 19% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 19 | David Westberg | www.nanexa.com |
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes.
Nanexa AB (publ) Fundamentals Summary
| 40M fundamental statistics | |
|---|---|
| Market cap | €15.01m |
| Earnings (TTM) | -€5.72m |
| Revenue (TTM) | €4.58m |
3.3x
P/S Ratio-2.6x
P/E RatioIs 40M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 40M income statement (TTM) | |
|---|---|
| Revenue | SEK 53.39m |
| Cost of Revenue | SEK 20.25m |
| Gross Profit | SEK 33.14m |
| Other Expenses | SEK 99.82m |
| Earnings | -SEK 66.68m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
| Earnings per share (EPS) | -0.49 |
| Gross Margin | 62.07% |
| Net Profit Margin | -124.89% |
| Debt/Equity Ratio | 1.8% |
How did 40M perform over the long term?
See historical performance and comparison